Alnylam Pharmaceuticals Inc (ALNY)
235.56
-22.35
(-8.67%)
USD |
NASDAQ |
Nov 15, 16:00
239.10
+3.54
(+1.50%)
After-Hours: 20:00
Alnylam Pharmaceuticals Research and Development Expense (TTM): 1.098B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.098B |
| June 30, 2024 | 1.080B |
| March 31, 2024 | 1.035B |
| December 31, 2023 | 1.004B |
| September 30, 2023 | 994.31M |
| June 30, 2023 | 986.50M |
| March 31, 2023 | 943.69M |
| December 31, 2022 | 883.02M |
| September 30, 2022 | 850.03M |
| June 30, 2022 | 799.23M |
| March 31, 2022 | 776.15M |
| December 31, 2021 | 792.16M |
| September 30, 2021 | 731.58M |
| June 30, 2021 | 698.79M |
| March 31, 2021 | 671.15M |
| December 31, 2020 | 654.82M |
| September 30, 2020 | 687.65M |
| June 30, 2020 | 686.66M |
| March 31, 2020 | 695.56M |
| December 31, 2019 | 655.11M |
| September 30, 2019 | 584.85M |
| June 30, 2019 | 564.00M |
| March 31, 2019 | 537.69M |
| December 31, 2018 | 505.42M |
| September 30, 2018 | 492.16M |
| Date | Value |
|---|---|
| June 30, 2018 | 447.46M |
| March 31, 2018 | 400.51M |
| December 31, 2017 | 390.64M |
| September 30, 2017 | 377.87M |
| June 30, 2017 | 380.56M |
| March 31, 2017 | 373.10M |
| December 31, 2016 | 382.39M |
| September 30, 2016 | 360.22M |
| June 30, 2016 | 330.90M |
| March 31, 2016 | 314.73M |
| December 31, 2015 | 276.50M |
| September 30, 2015 | 249.21M |
| June 30, 2015 | 226.86M |
| March 31, 2015 | 204.53M |
| December 31, 2014 | 190.25M |
| September 30, 2014 | 166.81M |
| June 30, 2014 | 154.99M |
| March 31, 2014 | 134.54M |
| December 31, 2013 | 112.96M |
| September 30, 2013 | 102.53M |
| June 30, 2013 | 90.17M |
| March 31, 2013 | 87.67M |
| December 31, 2012 | 86.57M |
| September 30, 2012 | 88.26M |
| June 30, 2012 | 90.44M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
654.82M
Minimum
Dec 2020
1.098B
Maximum
Sep 2024
836.22M
Average
795.69M
Median
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc | 10.60B |
| BridgeBio Pharma Inc | 506.34M |
| Gilead Sciences Inc | 8.104B |
| Johnson & Johnson | 16.41B |
| Regeneron Pharmaceuticals Inc | 4.897B |